NR1H4 and fatty liver disease: Specifically, TMAO blocks bile acid-activated farnesoid X receptor (FXR) signaling and reduces key bile acid synthesis enzymes (Cyp7a1, Cyp27a1), limiting bile acid production and increasing fatty liver risk (Koeth et al., 2013; Tan et al., 2019) (Figure 2).